These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32432841)

  • 21. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
    Feller CN; Adams JA; Friedland DR; Poetker DM
    Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.
    Parambil JG; Gossage JR; McCrae KR; Woodard TD; Menon KVN; Timmerman KL; Pederson DP; Sprecher DL; Al-Samkari H
    Angiogenesis; 2022 Feb; 25(1):87-97. PubMed ID: 34292451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report.
    García-Martín E; Pernía-López S; Martínez-Ortega PA; Monje B; Ruiz-Martínez C; Sanjurjo-Saez M
    Eur J Hosp Pharm; 2019 Jul; 26(4):226-228. PubMed ID: 31338174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
    Amann A; Steiner N; Gunsilius E
    Wien Klin Wochenschr; 2015 Aug; 127(15-16):631-4. PubMed ID: 25986996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
    Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
    J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia].
    Zhang J; Wang XS; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995
    [No Abstract]   [Full Text] [Related]  

  • 31. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
    Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
    Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
    Kanellopoulou T; Alexopoulou A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
    Harrison L; Kundra A; Jervis P
    J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy.
    Albitar HAH; Almodallal Y; Gallo De Moraes A; O'Brien E; Choby GW; Pruthi RK; Stokken JK; Kamath PS; Cajigas HR; DuBrock HM; Krowka MJ; Iyer VN
    Mayo Clin Proc; 2020 Aug; 95(8):1604-1612. PubMed ID: 32753135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
    Sautter NB; Smith TL
    Otolaryngol Clin North Am; 2016 Jun; 49(3):639-54. PubMed ID: 27267016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
    Guilhem A; Fargeton AE; Simon AC; Duffau P; Harle JR; Lavigne C; Carette MF; Bletry O; Kaminsky P; Leguy V; Lerolle N; Roux D; Lambert M; Chinet T; Bonnet D; Dupuis-Girod S; Rivière S
    PLoS One; 2017; 12(11):e0188943. PubMed ID: 29190827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
    Vázquez C; Gonzalez ML; Ferraris A; Bandi JC; Serra MM
    PLoS One; 2020; 15(2):e0228486. PubMed ID: 32032395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.